Ocular Therapeutix Inc
NASDAQ:OCUL
| Market Cap (Intraday) | 1.40B |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $18.58 |
| 50-Day MA | $19.94 |
| 200-Day MA | $12.47 |
Ocular Therapeutix, Inc. Stock, NASDAQ:OCUL
15 Crosby Drive, 24 Crosby Drive, Bedford, Massachusetts 01730
United States of America
Phone: +1.781.357.4000
Number of Employees: 161
Description
Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.